—A Pharmacor Analyst Call from Decision Resources
Based on our Pharmacor advisory service entitled Acute Coronary Syndrome, Decision Resources is offering this exclusive analyst call entitled Mixed Fortunes for Xarelto and Vorapaxar in Acute Coronary Syndrome – What Does the Future Hold for These Novel Oral Antithrombotics? Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service.
Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
Based on impressive Phase III clinical trial data from ATLAS ACS 2 TIMI 51, presented at the American Heart Association’s Scientific Sessions 2011 conference, Bayer/Johnson & Johnson’s oral Factor Xa inhibitor Xarelto appears to have succeeded where BMS/Pfizer’s Eliquis failed, by demonstrating a reduction in cardiovascular mortality versus placebo, on top of dual antiplatelet therapy. However, this came at a cost of a significant increase in bleeding risk and in intracranial hemorrhage, but not in fatal bleeding. Meanwhile, in the TRACER trial, Merck’s vorapaxar showed a non-significant 8 percent reduction in the first occurrence of heart attack, stroke and recurrent ischemia. Again, as was the case with Xarelto, the addition of a third oral antithrombotic agent lead to increased bleeding events, including hemorrhagic stroke.
This 15-minute analyst call, presented by Conor Walsh, Ph.D., will answer the following questions:
- Has physician perception of adding an additional antithrombotic to dual antiplatelet therapy changed following the results of ATLAS ACS 2 TIMI 51 and TRACER trials?
- In which ACS patients would physicians use Xarelto and what are the main factors that would limit its use?
- Which antithrombotic treatment strategy do physicians perceive to be superior?
Dr. Walsh will conduct a live Q & A session after the presentation.
Mixed Fortunes for Xarelto and Vorapaxar in Acute Coronary Syndrome – What Does the Future Hold for These Novel Oral Antithrombotics?
November 29, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.
Webinar Details Date & Time Duration: 15 minutes |
About the Speaker
|
Conor Walsh, Ph.D., M.Sc., is an analyst on the cardiovascular and metabolic disorders team at Decision Resources, where he currently specializes in the analysis of acute coronary syndrome. Prior to joining the company, he worked at Medical Marketing Research International. Dr. Walsh holds an M.Sc. in bioinformatics and a Ph.D. in cardiac structural biology, both from the University of Manchester. For his doctoral work, he studied the molecular mechanisms underlying heart failure. Dr. Walsh earned his B.Sc. in biotechnology with first class honors from the National University of Ireland in Galway.In North America | Keith Rourke | 781-993-2656
In Europe | Kaj van Langendonck | +32-2-357-06-14
In Japan | Makiko Yoshimoto | +81-3-5401-2615
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
